Rhumatologie. Canakinumab: un traitement prometteur [Canakinumab: a promising treatment in rheumatology].

Details

Serval ID
serval:BIB_49E2B4293272
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Rhumatologie. Canakinumab: un traitement prometteur [Canakinumab: a promising treatment in rheumatology].
Journal
Revue Médicale Suisse
Author(s)
Fabreguet I., So A.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2012
Volume
8
Number
323
Pages
57-60
Language
french
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Abstract
In auto-inflammatory diseases, the role of the inflammasome and the interleukine IL-1beta has recently been shown. Thus, the physiopathology of rare diseases as Cryopyrin-associated periodic syndrome (CAPS) is better understood. In the era of biologics, new treatments targeting IL-1 have been developped. Canakinumab is a fully humanized monoclonal antibody inhibiting specifically IL-1beta Clinical studies have shown its efficacy on clinical symptoms and on inflammatory markers in patients with rare diseases such as CAPS or idiopathic juvenile arthritis, but also in more common rheumatic conditions like gout. Canakinumab has been approved in Switzerland only for the treatment of CAPS. Studies evaluating its effect on cardiovascular diseases are ongoing.
Keywords
Antibodies, Monoclonal/therapeutic use, Arthritis, Gouty/drug therapy, Arthritis, Juvenile Rheumatoid/drug therapy, Biological Markers/blood, Cryopyrin-Associated Periodic Syndromes/drug therapy, Cryopyrin-Associated Periodic Syndromes/immunology, Humans, Inflammasomes/immunology, Inflammation/immunology, Interleukin-1beta/immunology, Rheumatic Diseases/diagnosis, Rheumatic Diseases/drug therapy, Rheumatology/trends, Treatment Outcome
Pubmed
Create date
06/06/2012 18:18
Last modification date
20/08/2019 13:57
Usage data